Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder
In a pilot randomised controlled trial of 20 participants with alcohol use disorder, viewing a nature-themed "Visual Healing" video during preparation and the ascent/descent phases of 25 mg psilocybin sessions was feasible, safe and well tolerated. Compared with standard procedures (eyeshades and music), Visual Healing significantly attenuated peak post‑psilocybin blood pressure increases while producing similar psychedelic effects and reductions in alcohol use.
Authors
- Heinzerling, K. G.
- Sergi, K.
- Linton, M.
Published
Abstract
Introduction
Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2 trials for alcohol use disorder (AUD). Set and setting, particularly factors facilitating a connection with nature, may positively influence the psychedelic experience and therapeutic outcomes. But to date, randomized controlled trials of interventions to enhance set and setting for psychedelic-assisted therapy are lacking.
Methods
This was a pilot randomized, controlled trial of Visual Healing, a nature-themed video intervention to optimize set and setting, versus Standard set and setting procedures with two open-label psilocybin 25 mg dosing sessions among 20 participants with AUD. For the first session, participants randomized to Visual Healing viewed nature-themed videos during the preparation session and the “ascent” and “descent” phases of the psilocybin dosing session while participants randomized to the Standard condition completed a meditation during the preparatory session and wore eyeshades and listened to a music playlist throughout the dosing session. For the second session 4 weeks later, participants chose either Visual Healing or Standard procedures. Primary outcomes were feasibility, safety, and tolerability of Visual Healing. Secondary and exploratory outcomes were changes in alcohol use, psychedelic effects, anxiety and stress.
Results
Nineteen of 20 (95%) randomized participants (mean age 49 ± 11 years, 60% female) completed the 14-week study. During the first psilocybin session, participants viewed an average of 37.9 min of the 42-min video and there were no video-related adverse events. Peak increase in post-psilocybin blood pressure was significantly less for participants randomly assigned to Visual Healing compared to Standard procedures. Alcohol use decreased significantly in both Visual Healing and Standard groups and psychedelic effects, stress, and anxiety were similar between groups.
Discussion
In this open-label pilot study, viewing Visual Healing videos during preparation and psilocybin dosing sessions was feasible, safe, and well-tolerated among participants with AUD. Preliminary findings suggest that Visual Healing has potential to reduce the cardiovascular risks of psychedelic therapy, without interfering with the psychedelic experience or alcohol-related treatment outcomes. Studies to replicate our findings as well as studies of different set and setting interventions with other psychedelic medications and indications are warranted.
Research Summary of 'Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder'
Introduction
Heinzerling and colleagues situate their study within renewed interest in psychedelic-assisted therapies for alcohol use disorder (AUD), noting historical and recent positive findings for LSD and psilocybin. Earlier trials suggested single doses of psychedelics can reduce drinking for months, and a recent randomized, placebo-controlled trial found psilocybin plus counselling reduced percent heavy drinking days. The authors emphasise that ‘‘set and setting’’ — the participant's mindset and the physical/social environment — shape psychedelic experiences and outcomes, and that interventions which foster connection with nature have been associated with reduced stress and blood pressure in other healthcare contexts. Despite this, randomised trials testing set-and-setting augmentations for psychedelic therapy are lacking. This pilot study tested whether a purpose-made nature-themed video intervention, ‘‘Visual Healing’’, is feasible, safe, and tolerable when integrated into psilocybin-assisted therapy for AUD, and whether it affects clinical and physiological outcomes. The investigators hypothesised that Visual Healing might reduce pre-session anxiety and post-psilocybin cardiovascular responses, increase feelings of nature connectedness and potentially augment mystical or therapeutic effects, without disrupting the psychedelic experience. The trial therefore compared Visual Healing versus standard set-and-setting (eyes-shades and music) during the first of two open-label 25 mg psilocybin dosing sessions, with choice of procedure for the second session.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- APA Citation
Heinzerling, K. G., Sergi, K., Linton, M., Rich, R., Youssef, B., Bentancourt, I., Bramen, J., Siddarth, P., Schwartzberg, L., & Kelly, D. F. (2023). Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1215972
References (20)
Papers cited by this study that are also in Blossom
Schenberg, E. E. · Frontiers in Pharmacology (2018)
Dyck, E. · Canadian Journal of Psychiatry (2005)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Bogenschutz, M. P., Ross, S., Bhatt, S. R. et al. · JAMA Psychiatry (2022)
Hartogsohn, I. · Drug Science Policy and Law (2017)
Simonsson, O., Hendricks, P. S., Chambers, R. et al. · Journal of Affective Disorders (2023)
Haijen, E. C. H. M., Kaelen, M., Roseman, L. et al. · Frontiers in Pharmacology (2018)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Nikolaidis, A., Lancelotta, R., Gukasyan, N. et al. · Journal of Affective Disorders (2023)
Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)
Show all 20 referencesShow fewer
Watts, R., Kettner, H., Gandy, S. et al. · Psychopharmacology (2022)
Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)
Carhart-Harris, R. L., Erritzoe, D., Haijen, E. C. H. M. et al. · Psychopharmacology (2017)
Gandy, S., Forstmann, M., Carhart-Harris, R. L. et al. · Health Psychology Open (2020)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Calleja-Conde, J., Morales-García, J. A., Echeverry-Alzate, V. et al. · Addiction Biology (2022)
Grabski, M., McAndrew, A., Lawn, W. et al. · American Journal of Psychiatry (2022)
Dakwar, E., Levin, F. R., Hart, C. L. et al. · American Journal of Psychiatry (2020)
Hartogsohn, I. · Frontiers in Human Neuroscience (2018)
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G. et al. · Psychopharmacology (2014)
Cited By (2)
Papers in Blossom that reference this study
Fink-Jensen, A., Jensen, M. E., Stenbæk, D. S. et al. · Journal of Psychopharmacology (2025)
Hinkle, J. T., Graziosi, M., Nayak, S. et al. · JAMA Psychiatry (2024)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.